Market Size
The global focal segmental glomerulosclerosis drugs market reached US$ 0.7 billion in 2023 and is expected to reach US$ 1.4 billion by 2031, growing at a CAGR of 7.5% during the forecast period 2024-2031.
Focal segmental glomerulosclerosis is a type of renal disorder affecting the small filtering unit of kidneys called glomeruli which involves scarring of the kidney. It is caused by numerous factors such as autoimmune disorders, genetic factors, infection in other parts of the body, and sclerotic diseases.
It is one of the rare diseases that affects kidney function by damaging and attacking the glomeruli. Kidney defects typically characterize this disease by obesity, sickle cell anemia, obstructive sleep apnea, birth, and viruses such as HIV.
Market Scope
| Metrics | Details |
| CAGR | 7.5% |
| Market Size | 2022-2031 |
| Market Estimation Forecast Period | 2024-2031 |
| Revenue Units | Value (US$ Mn) |
| Segments Covered | Disease Type, Drugs, Route of Administration, Distribution Channel, and End-User |
| Regions Covered | North America, Europe, Asia-Pacific, South America, and Middle East & Africa |
| Largest Region | North America |
| Fastest Growing Region | Asia-Pacific |
| Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and Acquisitions, New Launches, Growth Strategies, Revenue Analysis, Porter's Analysis, Pricing Analysis, Regulatory Analysis, Supply-Chain Analysis, and Other key Insights. |
For more details on this report - Request for Sample
Market Dynamics: Drivers
The rising burden of focal segmental glomerulosclerosis drugs(FSGS)
The demand for the global focal segmental glomerulosclerosis drugs market is driven by multiple factors. One of the key factors is the increasing burden of FSGS. Focal segmental glomerulosclerosis drugs(FSGS) is a disease in which scar tissue develops on the glomeruli, the small parts of the kidneys that filter waste from the blood.
FSGS can be caused by a variety of conditions. FSGS is a serious condition that can lead to kidney failure, which can only be treated with dialysis or a kidney transplant.
According to an NCBI research publication in August 2023, focal segmental glomerular sclerosis (FSGS) is a frequently encountered cause of nephrotic syndrome, accounting for 40% of cases in adults and 20% in children.
In addition, a high focus on developing new treatment options is expected to drive the growth of this market over the forecast period. For instance, in February 2023, the drug, called sparsentan, snagged an FDA accelerated approval to treat patients with primary immunoglobulin A nephropathy (IgAN) who are at risk of rapid disease progression.
Moreover, IgAN, Travere is also developing Filspari for focal segmental glomerulosclerosis drugs(FSGS), an even rarer kidney disease in which scar tissue develops on the kidney’s waste filter glomeruli. About 90% of patients diagnosed with IgAN are currently on an ACE inhibitor or an ARB.
Restraints
Factors such as the high cost of dialysis & kidney transplant, limited awareness of FSGS, limited availability of effective treatment options, and stringent regulatory and reimbursement policies, are expected to hamper the market.
Segment Analysis
The global focal segmental glomerulosclerosis drugs market is segmented based on disease type, drugs, route of administration, distribution channel, end-user, and region.
The primary focal segmental glomerulosclerosis drugs segment accounted for approximately 45.3% of the global focal segmental glomerulosclerosis drugs market share
The primary focal segmental glomerulosclerosis drugs segment is expected to hold the largest market share over the forecast period. The primary FSGS is usually "idiopathic," referring to the rise of disease without any known, definite, or apparent reason. It has several prototypical characteristics and is the most common form in adolescents and young adults.
Primary FSGS has been associated with the presence of circulating permeability factors/cytokines, which cause foot process effacement and proteinuria. These include corticotrophin-like cytokine factor 1, apoA1b, anti-CD40 Ab, and suPAR. Primary FSGS may respond to corticosteroids, immunomodulatory agents, plasmapheresis, or immunoadsorption and is prone to recur post-transplantation.
Moreover, key players' focus on innovative developments would propel this market growth. For instance, in May 2023, CSL Vifor announced topline primary efficacy results from the pivotal Phase 3 DUPLEX Study of sparsentan, a Dual Endothelin Angiotensin Receptor Antagonist (DEARA), in focal segmental glomerulosclerosis drugs(FSGS) from its partner Travere Therapeutics.
Also, in December 2023, Travere completed a successful pre-NDA meeting for FILSPARI in IgAN. It provides regulatory updates for both IgAN and FSGS.
IgAN is the most common type of primary glomerulonephritis worldwide and a leading cause of kidney failure due to glomerular disease. IgAN is estimated to affect up to 150,000 people in the U.S. and is one of the most common glomerular diseases in Europe and Japan.
Geographical Analysis
North America accounted for approximately 42.1% of the global focal segmental glomerulosclerosis drugs market share
North America region is expected to hold the largest market share over the forecast period. The high prevalence of FSGS in North America is driving the demand for effective FSGS therapeutics. The region has a well-established research and development infrastructure that is constantly driving innovation in FSGS therapeutics. As per Springer's research publication in September 2023, FSGS is predominant in North America, accounting for 19.1% of primary glomerular diseases.
In addition, a major key player's presence, increasing awareness of FSGS among healthcare professionals, and new drug approvals would drive this market growth. For instance, in May 2022, Travere Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) under Subpart H for accelerated approval of sparsentan to treat IgA nephropathy (IgAN) and has granted Priority Review.
Travere Therapeutics is looking forward to working with the FDA throughout the review process to potentially deliver sparsentan to the IgA nephropathy community.
Market Segmentation
By Disease Type
- Primary Focal Segmental Glomerulosclerosis
- Secondary Focal Segmental Glomerulosclerosis
By Drugs
- Corticosteroids
- Immunosuppressive Drugs
- ACE inhibitors
- Angiotensin Receptor Blockers
- Diuretics
- Others
By Route of Administration
- Oral
- Parenteral
By Distribution Channel
- Hospital Pharmacies
- Online Pharmacies
- Retail Pharmacies
By End-Users
- Hospitals
- Specialty Clinics
- Others
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- U.K.
- France
- Spain
- Italy
- Rest of Europe
- South America
- Brazil
- Argentina
- Rest of South America
- Asia-Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Middle East and Africa
Competitive Landscape
The major global players in the focal segmental glomerulosclerosis drugs market include GlaxoSmithKline plc, Pfizer Inc., Travere Therapeutics, Inc., Variant Pharmaceuticals, Inc., Dimerix, Complexa Inc., ChemoCentryx Inc., AstraZeneca, Novartis AG, and Vertex Pharmaceuticals Incorporated among others.
Key Developments
- In June 2023, Delta4 identified a potential new therapeutic option for focal segmental glomerulosclerosis drugs (FSGS) using the computational hyper-C drug discovery platform. The anti-platelet drug clopidogrel was among the top predictions and was shown to alleviate disease progression in an accepted FSGS animal model, suggesting it is a promising candidate for clinical trials.
- In May 2023, Travere had to deal with the FDA after Filspari door number two opens weak in the FSGS Duplex trial.
- In February 2022 Goldfinch Bio announced positive preliminary data from a phase 2 clinical trial evaluating gfb-887 as a precision medicine for patients with focal segmental glomerulosclerosis drugs (FSGS).
- In December 2021, Vertex Pharmaceuticals Incorporated announced that in a Phase 2 proof-of-concept (POC) study in patients with APOL1-mediated focal segmental glomerulosclerosis drugs(FSGS), VX-147 on top of standard of care achieved a statistically significant, substantial and clinically meaningful mean reduction of 47.6% in the urine protein to creatinine ratio (UPCR) at Week 13 compared to baseline.
Why Purchase the Report?
- To visualize the global focal segmental glomerulosclerosis drug market segmentation based on disease type, drugs, route of administration, distribution channel, end-user, and region, as well as understand key commercial assets and players.
- Identify commercial opportunities by analyzing trends and co-development
- Excel data sheet with numerous data points of global focal segmental glomerulosclerosis drugs market level with all segments.
- PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
- Product mapping is available in excel consisting of key products of all the major players.
The global focal segmental glomerulosclerosis market report would provide approximately 78 tables, 73 figures, and 181 Pages.
Target Audience 2024
- Manufacturers/ Buyers
- Industry Investors/Investment Bankers
- Research Professionals
- Emerging Companies
